Renascience

Renascience Capital Intensity

The Capital Intensity Ratio of Renascience (4889.T) as of Nov 19, 2026 is 5,110.22 %. In the previous year, Capital Intensity Ratio was 1,410.29 % — a change of 262.35% (higher).

Capital Intensity

5,110.22 %

YoY

262.35%

Last updated:

Capital Intensity Ratio of Renascience is 2026 5,110.22 % . Capital Intensity Ratio of Renascience was 2025 1,410.29 % . It decreases by 262.35% higher compared to the previous year.

The Renascience Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2020
1,406.45 JPY
Jan 1, 2021
508.40 JPY
Jan 1, 2022
1,749.79 JPY
Jan 1, 2023
2,262.49 JPY
Jan 1, 2024
1,075.80 JPY
Jan 1, 2025
1,410.29 JPY
Jan 1, 2026
5,110.22 JPY
The Renascience Capital Intensity history
YEARCapital IntensityYoY
5,110.22 %+262.35%
1,410.29 %+31.09%
1,075.80 %-52.45%
2,262.49 %+29.30%
1,749.79 %+244.18%
508.40 %-63.85%
1,406.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Capital Intensity Ratio of Renascience is 5,110.22 % in 2026.

Capital Intensity Ratio of Renascience changed from 1,410.29 % to 5,110.22 %, representing a 262.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Renascience since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Renascience with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Renascience

All Key Metrics — Renascience